Stock Analysis
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis
Arrowhead Pharmaceuticals, Inc. (ARWR) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Arrowhead Pharmaceuticals, Inc. (ARWR) currently has an AIQ Score of 42/100, indicating a neutral setup. Risk is the strongest factor at 58/100. Quality is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ARWR at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $86.34 |
| AIQ Score | 42/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Buy |
| Market Cap | $11.65B |
| P/E Ratio | -36.77 |
| Forward P/E | — |
| EPS | -$1.36 |
| Revenue TTM | $75.25M |
| Dividend Yield | 0.00% |
| Beta | 1.29 |
| Volume | 757.85K |
| 52-week range | $27.10-$95.49 |
| RSI 14 | 43.57 |
| 50-Day SMA | $84.01 |
| 200-Day SMA | $71.14 |
| Analyst Price Target | $103.09 |
| Next Earnings | Nov 24, 2026 |
ARWR
OverviewARWR Stock Analysis Summary
Arrowhead Pharmaceuticals, Inc. (ARWR) currently has an AIQ Score of 42/100, indicating a neutral setup. Risk resilience is the strongest factor at 58/100. Quality is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, ARWR has AIQ Score of 42/100 with Risk resilience base of 58/100 and fading Quality at 32/100. Wait for component alignment before adding exposure.
Risk resilience (58/100) leads while Quality (32/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.17% stock move · ARWR classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ARWR Bullish or Bearish Right Now?
ARWR currently has a neutral overall setup. Risk Resilience is the strongest factor at 58/100, while Quality is weakest at 32/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Price is +2.77% above its 50-day SMA.
- - Analyst target implies +19.40% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (22 vs 15).
- - Value is the current constraint at 34/100.
Current Consensus
ARWR's Technical Analysis Consensus is currently Buy, with 22 buy, 8 neutral, and 15 sell votes. ARWR's 14-day RSI is 43.57, which places the stock in a weaker momentum range. ARWR's beta is 1.29, indicating greater market sensitivity than the broad market.
What Changed in ARWR?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the ARWR Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ARWR Decision Framework
Public evidence layers, setup checks, and risk context for Arrowhead Pharmaceuticals, Inc..
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis
Arrowhead Pharmaceuticals, Inc. has an AIQ Score of 42/100 in a Neutral regime. Risk is strongest at 58/100. Beta is 1.29, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ARWR is in a Neutral AIQ regime with score 42/100. |
| Signal Conflict | The primary conflict is that risk leads at 58/100 while quality lags at 32/100. |
| Factor Evidence | Momentum 55/100 · Value 34/100 · Quality 32/100 · Risk 58/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 58/100.
Momentum is 55/100 and RSI (14) is 43.6.
ARWR is in a Neutral regime at 42/100.
Risk factor is 58/100 with beta 1.29 and annual volatility 61.43%.
Current conflict: risk leads at 58/100 while quality lags at 32/100.
ARWR Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ARWR Fundamentals
ARWR valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ARWR Technical Analysis
ARWR technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ARWR Stock Catalysts
Track ARWR earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ARWR Dividend Analysis
ARWR dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ARWR Financial Data
ARWR revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ARWR Risk Analysis
ARWR volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ARWR Stock News
ARWR stock news, market tone, recent headlines, and catalyst context.
ARWR vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: ARWR · BDTX · BEAM · CRSP · DNLI. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ARWR Current stock | 42/100 | 34/100 | 55/100 | 58/100 | 2.08 | 61.43% | Current |
| BDTX Black Diamond Therapeutics | 41/100 | — | 59/100 | 37/100 | 0.02 | 82.74% | ARWR vs BDTX |
| BEAM Beam Therapeutics | 44/100 | 34/100 | 71/100 | 36/100 | 0.94 | 75.40% | ARWR vs BEAM |
| CRSP CRISPR Therapeutics | 39/100 | 34/100 | 63/100 | 41/100 | 0.33 | 60.23% | ARWR vs CRSP |
| DNLI Denali Therapeutics | 38/100 | 34/100 | 34/100 | 69/100 | 0.94 | 56.83% | ARWR vs DNLI |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 5, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 7, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ARWR
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ARWR
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ARWR Stock FAQ
What is ARWR stock price today?
Arrowhead Pharmaceuticals, Inc.'s current stock price is $86.34. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ARWR bullish or bearish right now?
ARWR's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ARWR's market cap?
ARWR's market cap is $11.65B based on the latest completed market-close snapshot from Sep 4, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ARWR's current P/E ratio?
ARWR's current P/E ratio is -36.77 based on the latest completed market-close snapshot from Sep 4, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ARWR's RSI?
ARWR's 14-day RSI is 43.57 based on the latest completed market-close snapshot from Sep 4, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ARWR above its 50-day and 200-day moving averages?
ARWR is 2.77% from its 50-day SMA and 21.37% from its 200-day SMA based on the latest completed market-close snapshot from Sep 4, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ARWR's next earnings date?
ARWR's next earnings date is currently listed as Nov 24, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ARWR pay a dividend?
ARWR's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 4, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.